Toray Licenses RADIFIL® Fast-Dissolving Film Coating Technology to Kishi Kasei

Toray Industries, Inc.,
Kishi Kasei Co., Ltd.

Tokyo, Japan, March 22, 2021 – Toray Industries, Inc., announced today that it has concluded an agreement to license its RADIFIL® (patent numbers 6443332 and 5696742) fast-dissolving film coating technology to Yokohama-based Kishi Kasei Co., Ltd.

The agreement grants Kishi Kasei the exclusive right to develop, manufacture and sell orally disintegrating tablet coating agents in Japan based on the RADIFIL® technology. That company will also have the right to use the RADIFIL® trademark. Toray will receive considerations including running royalties under this arrangement. Kishi Kasei will start supplying prototype coatings to pharmaceutical manufacturers through this technology transfer and looks to strengthen its pharmaceutical excipients business.

RADIFIL® employs two proprietary coating technologies for orally disintegrating tablets. One lightshields drug tablets containing photodegradable pharmaceutical active ingredients. The other moisture-proofs and creates a gas barrier for drug tablets containing highly hygroscopic active pharmaceutical ingredients. Both technologies maintain tablets’ fast disintegration.

Toray’s RADIFIL® technologies received an Encouragement Prize for Invention from the Japan Institute of Invention and Innovation in 2018 and the 2019 Asahi Kasei Pharmaceutical Technology Award from the Academy of Pharmaceutical Science and Technology.

Patients can take orally disintegrating tablets with or without water. This greatly contributes enhancement in medication compliance for the elderly, who find swallowing harder, and those needing to limit fluid intakes. Toray and Kishi Kasei will keep striving to help maintain and improve consumer health through innovative formulation technologies.

The licensing agreement with Kishi Kasei excludes film-coating technology for tablets containing nalfurafine hydrochloride which is the active ingredient in Remitch® (see note) OD tablets 2.5μg, an oral antipruritus drug for which Toray has obtained a marketing authorization.